In addition, there is much evidence to show that GLP-1-related drugs attenuate hepatic steatosis through targeting the hepatic lipid metabolism, including inhibiting lipogenesis (10,23), promoting fatty acid β-oxidation (10,24), increasing fatty acid transport (24) and enhancing lipid droplet fission (25). This evidence concerns the gene GCG and fatty liver disease.